Pharmacologic class (EPC) · 2 drug pages

Selective T cell costimulation modulator: adverse event reports filed with FDA

130,919 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

130,919
reports across the class: 0.6% of all reports; 8,496
reports, 12 months to June 2026: 9,741 in the 12 months before; 60.2%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Selective T cell costimulation modulator is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 130,919 adverse event reports received by FDA, 0.6% of the database, from June 2004 to June 2026.

8,496 reports arrived in the 12 months to June 2026, down 13% from 9,741 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 60.2% of the class's reports are marked serious, 7% record death among the outcomes and 18.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (28.6%), rheumatoid arthritis (18%) and pain (16.4%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
OrenciaAbatacept	brand	108,772	8,143	53.1%	Drug ineffective
Abatacept	generic	22,147	353	95.1%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected28.6%37,379
Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease18%23,610
Painpain, site not specified16.4%21,422
Arthralgiajoint pain15.9%20,787
Joint swellinga swollen joint15.5%20,235
Contraindicated product administered11%14,409
Fatiguetiredness10.9%14,209
Rashskin rash10.2%13,327
Drug intolerancethe medicine was not tolerated10.1%13,189
Off label useused for a purpose or in a way not on the label9.1%11,957
Arthropathy9.1%11,875
Alopeciahair loss8.2%10,726
Synovitis8%10,506
Abdominal discomfortstomach discomfort7.8%10,245
Swellingswelling7.6%9,949
Treatment failurethe treatment did not work7.5%9,877
Hypersensitivityan allergic-type reaction7.5%9,824
Systemic lupus erythematosuslupus, an autoimmune disease7.3%9,599
Headachehead pain7%9,212
Pemphigus6.9%9,047
Condition aggravatedthe condition being treated got worse6.9%9,001
Infectionan infection, type not specified6.5%8,575
Drug hypersensitivityan allergic-type reaction to a medicine6.4%8,428
Glossodynia6.4%8,395
Peripheral swellingswelling of the arms or legs6.4%8,323

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death7%9,171

Life-threatening5.3%6,912

Hospitalisation (initial or prolonged)18.5%24,196

Disability7.2%9,401

Congenital anomaly1.9%2,462

Other serious52.8%69,136

Not serious39.8%52,119

Patient age

Under 20.1%84

2 to 110.4%541

12 to 170.6%780

18 to 4410.5%13,733

45 to 6428.7%37,597

65 to 7414.1%18,508

75 and over8.8%11,564

Age not given36.7%48,112

Who reported

Physician13.5%17,728

Pharmacist5%6,587

Other health professional43.1%56,433

Lawyer0%9

Consumer or non-health professional37.4%48,903

Not given1%1,259

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Selective T cell costimulation modulator reports

Which drugs are in the Selective T cell costimulation modulator class on this site?

Orencia and Abatacept. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

130,919 reports through June 2026, 8,496 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (28.6%), rheumatoid arthritis (18%), pain (16.4%), arthralgia (15.9%) and joint swelling (15.5%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.